205 related articles for article (PubMed ID: 11122027)
41. Elevated levels of interleukin-9 in the serum of bullous pemphigoid: possible association with the pathogenicity of bullous pemphigoid.
Koga H; Teye K; Sugawara A; Tsutsumi M; Ishii N; Nakama T
Front Immunol; 2023; 14():1135002. PubMed ID: 37398641
[TBL] [Abstract][Full Text] [Related]
42. Bullous pemphigoid outcome is associated with CXCL10-induced matrix metalloproteinase 9 secretion from monocytes and neutrophils but not lymphocytes.
Riani M; Le Jan S; Plée J; Durlach A; Le Naour R; Haegeman G; Bernard P; Antonicelli F
J Allergy Clin Immunol; 2017 Mar; 139(3):863-872.e3. PubMed ID: 27637385
[TBL] [Abstract][Full Text] [Related]
43. Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.
Amber KT; Murrell DF; Schmidt E; Joly P; Borradori L
Clin Rev Allergy Immunol; 2018 Feb; 54(1):26-51. PubMed ID: 28779299
[TBL] [Abstract][Full Text] [Related]
44. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model.
Li Q; Ujiie H; Shibaki A; Wang G; Moriuchi R; Qiao HJ; Morioka H; Shinkuma S; Natsuga K; Long HA; Nishie W; Shimizu H
J Immunol; 2010 Dec; 185(12):7746-55. PubMed ID: 21076071
[TBL] [Abstract][Full Text] [Related]
45. Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study.
Spronk PE; ter Borg EJ; Huitema MG; Limburg PC; Kallenberg CG
Ann Rheum Dis; 1994 Apr; 53(4):235-9. PubMed ID: 8203951
[TBL] [Abstract][Full Text] [Related]
46. Bullous pemphigoid: role of complement and mechanisms for blister formation within the lamina lucida.
Iwata H; Kitajima Y
Exp Dermatol; 2013 Jun; 22(6):381-5. PubMed ID: 23651418
[TBL] [Abstract][Full Text] [Related]
47. Increased serum levels of interleukin (IL)-5, IL-6 and IL-8 in bullous pemphigoid.
Inaoki M; Takehara K
J Dermatol Sci; 1998 Jan; 16(2):152-7. PubMed ID: 9459128
[TBL] [Abstract][Full Text] [Related]
48. The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.
Kramer MD; Reinartz J
J Clin Invest; 1993 Aug; 92(2):978-83. PubMed ID: 7688770
[TBL] [Abstract][Full Text] [Related]
49. Lesional Th17 cells and regulatory T cells in bullous pemphigoid.
Arakawa M; Dainichi T; Ishii N; Hamada T; Karashima T; Nakama T; Yasumoto S; Tsuruta D; Hashimoto T
Exp Dermatol; 2011 Dec; 20(12):1022-4. PubMed ID: 22017210
[TBL] [Abstract][Full Text] [Related]
50. Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid.
Toosi S; Bystryn JC
Med Hypotheses; 2010 Apr; 74(4):727-8. PubMed ID: 19945799
[TBL] [Abstract][Full Text] [Related]
51. Role of different pathways of the complement cascade in experimental bullous pemphigoid.
Nelson KC; Zhao M; Schroeder PR; Li N; Wetsel RA; Diaz LA; Liu Z
J Clin Invest; 2006 Nov; 116(11):2892-900. PubMed ID: 17024247
[TBL] [Abstract][Full Text] [Related]
52. Interleukin-26-DNA complexes promote inflammation and dermal-epidermal separation in a modified human cryosection model of bullous pemphigoid.
Mizuno Y; Shibata S; Ito Y; Taira H; Sugimoto E; Awaji K; Sato S
Front Immunol; 2022; 13():1013382. PubMed ID: 36311716
[TBL] [Abstract][Full Text] [Related]
53. Increased serum IL-6, TNF-alpha and IL-10 levels in patients with bullous pemphigoid: relationships with disease activity.
D'Auria L; Mussi A; Bonifati C; Mastroianni A; Giacalone B; Ameglio F
J Eur Acad Dermatol Venereol; 1999 Jan; 12(1):11-5. PubMed ID: 10188143
[TBL] [Abstract][Full Text] [Related]
54. Blister Fluid Induces MMP-9-Associated M2-Type Macrophages in Bullous Pemphigoid.
Riani M; Muller C; Bour C; Bernard P; Antonicelli F; Le Jan S
Front Immunol; 2019; 10():1858. PubMed ID: 31440247
[TBL] [Abstract][Full Text] [Related]
55. Epidermal interleukin-8 and its receptor CXCR2 in drug-induced toxic epidermal necrolysis.
Paquet P; Ribbens C; Piérard GE
Clin Exp Dermatol; 2007 Nov; 32(6):728-32. PubMed ID: 17714530
[TBL] [Abstract][Full Text] [Related]
56. In vivo analysis of IgE autoantibodies in bullous pemphigoid: a study of 100 cases.
Moriuchi R; Nishie W; Ujiie H; Natsuga K; Shimizu H
J Dermatol Sci; 2015 Apr; 78(1):21-5. PubMed ID: 25724363
[TBL] [Abstract][Full Text] [Related]
57. Changes in soluble CD4 and CD8 proteins in healthy pregnant and postpartum women.
Watanabe M; Iwatani Y; Hidaka Y; Mitsuda N; Amino N
Am J Reprod Immunol; 1996 Oct; 36(4):220-7. PubMed ID: 8911630
[TBL] [Abstract][Full Text] [Related]
58. Detection of anti-BP180NC16a and anti-BP230 autoantibodies in blister fluid of patients with bullous pemphigoid: the first survey in Greece.
Patsatsi A; Vyzantiadis TA; Devliotou-Panagiotidou D; Chrysomallis F; Sotiriadis D
Clin Exp Dermatol; 2008 Mar; 33(2):183-5. PubMed ID: 18093242
[TBL] [Abstract][Full Text] [Related]
59. Role of cell-mediated immune reaction in blister formation of bullous pemphigoid.
Kaneko F; Minagawa T; Takiguchi Y; Suzuki M; Itoh N
Dermatology; 1992; 184(1):34-9. PubMed ID: 1558993
[TBL] [Abstract][Full Text] [Related]
60. Serum soluble CD4 and CD8 levels in polymyalgia rheumatica.
Salvarani C; Boiardi L; Macchioni P; Casadei Maldini M; Mancini R; Beltrandi E; Rossi F; Portioli I
J Rheumatol; 1994 Oct; 21(10):1865-9. PubMed ID: 7837152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
